Literature DB >> 16002911

B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea.

Philippe Gabriel Steg1, Laurence Joubin, James McCord, William T Abraham, Judd E Hollander, Torbjorn Omland, France Mentré, Peter A McCullough, Alan S Maisel.   

Abstract

BACKGROUND: Echocardiography and B-type natriuretic peptide (BNP) are diagnostic tests for congestive heart failure (CHF), but an emergency diagnosis can be difficult.
OBJECTIVE: To assess the diagnostic performance of BNP testing and echocardiographic assessment of left ventricular systolic function, separately and combined, for the identification of CHF in patients with acute dyspnea.
DESIGN: Prospective, multinational, multicenter study.
SETTING: Patients presenting to emergency departments in seven hospitals between June 1999 and December 2000. PATIENTS: A total of 1,586 patients with acute dyspnea. MAIN OUTCOME MEASURES: Echocardiographic determination of ejection fraction (EF) and point-of care BNP measurement for the diagnosis of CHF.
RESULTS: Seven hundred nine of the 1,586 patients underwent echocardiography; 492 patients (69.4%) had a final diagnosis of CHF. Patients with CHF were older (68.5 years vs 61.6 years, p < 0.0001), had a lower EF (39.5% vs 56.1%, p < 0.0001), and a higher BNP (683 pg/mL vs 129 pg/mL, p < 0.0001) than patients without CHF. Area under the receiver operating characteristic (ROC) curve for the diagnosis of CHF was significantly higher for BNP (0.89) than for EF (0.78; area under the ROC curve difference, 0.12; p < 0.0001). The sensitivity of BNP > or = 100 pg/mL for the diagnosis of CHF was 89%, and specificity was 73%. Values for EF < or = 50% had a sensitivity of 70% and a specificity of 77%. Multivariate logistic regression analysis showed that, in combination with clinical, ECG, and chest radiograph data, BNP > or = 100 pg/mL and EF < or = 50% remained independent predictors of CHF (odds ratios, 32.1 and 6.2, respectively). The proportions of patients who were correctly classified were 67% for BNP alone, 55% for EF alone, 82% for the two variables together, and 97.3% when clinical, ECG, and chest radiograph data were added.
CONCLUSION: BNP measurement was superior to two-dimensional echocardiographic determination of EF in identifying CHF, regardless of the threshold value. The two methods combined have marked additive diagnostic value.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16002911     DOI: 10.1378/chest.128.1.21

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  12 in total

Review 1.  Use of BNP and NT-proBNP for the diagnosis of heart failure in the emergency department: a systematic review of the evidence.

Authors:  Stephen A Hill; Ronald A Booth; P Lina Santaguida; Andrew Don-Wauchope; Judy A Brown; Mark Oremus; Usman Ali; Amy Bustamam; Nazmul Sohel; Robert McKelvie; Cynthia Balion; Parminder Raina
Journal:  Heart Fail Rev       Date:  2014-08       Impact factor: 4.214

Review 2.  Aerobic exercise effect on prognostic markers for systolic heart failure patients: a systematic review and meta-analysis.

Authors:  Gerson Cipriano; Vivian T F Cipriano; Vinicius Z Maldaner da Silva; Graziella F B Cipriano; Gaspar R Chiappa; Alexandra C G B de Lima; Lawrence P Cahalin; Ross Arena
Journal:  Heart Fail Rev       Date:  2014-09       Impact factor: 4.214

3.  Prevalence and treatment of central sleep apnoea emerging after initiation of continuous positive airway pressure in patients with obstructive sleep apnoea without evidence of heart failure.

Authors:  Michael Westhoff; Michael Arzt; Patric Litterst
Journal:  Sleep Breath       Date:  2011-02-25       Impact factor: 2.816

4.  Biomarkers in heart failure--better than history or echocardiography?

Authors:  Dominik Berliner; Christiane E Angermann; Georg Ertl; Stefan Störk
Journal:  Herz       Date:  2009-12       Impact factor: 1.443

Review 5.  [Differential diagnosis of dyspnea - significance of clinic aspects, imaging and biomarkers for the diagnosis of heart failure].

Authors:  C Angermann; C Hoyer; G Ertl
Journal:  Clin Res Cardiol       Date:  2006       Impact factor: 5.460

Review 6.  New and emerging biomarkers in left ventricular systolic dysfunction--insight into dilated cardiomyopathy.

Authors:  Deepa M Gopal; Flora Sam
Journal:  J Cardiovasc Transl Res       Date:  2013-04-23       Impact factor: 4.132

7.  Use of N-terminal pro-brain natriuretic peptide to detect cardiac origin in critically ill cancer patients with acute respiratory failure.

Authors:  Aurélie Lefebvre; Suzanne Kural-Menasché; Michael Darmon; Guillaume Thiéry; Jean-Paul Feugeas; Benoît Schlemmer; Elie Azoulay
Journal:  Intensive Care Med       Date:  2008-01-24       Impact factor: 17.440

8.  Diagnosis of new onset heart failure in the community: the importance of a shared-care approach and judicious use of BNP.

Authors:  G Mak; M Ryder; N F Murphy; C O'Loughlin; D McCaffrey; M Ledwidge; K McDonald
Journal:  Ir J Med Sci       Date:  2008-07-17       Impact factor: 1.568

9.  B-type natriuretic peptide as a marker for heart failure in patients with acute stroke.

Authors:  Matthew A Koenig; H Adrian Puttgen; Vivek Prabhakaran; Daniel Reich; Robert D Stevens
Journal:  Intensive Care Med       Date:  2007-05-31       Impact factor: 17.440

Review 10.  Current clinical applications of spectral tissue Doppler echocardiography (E/E' ratio) as a noninvasive surrogate for left ventricular diastolic pressures in the diagnosis of heart failure with preserved left ventricular systolic function.

Authors:  Stephane Arques; Emmanuel Roux; Roger Luccioni
Journal:  Cardiovasc Ultrasound       Date:  2007-03-26       Impact factor: 2.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.